Novartis Respiratory Franchise Sits On FDA Launch Pad; Can It Achieve Orbit?
Executive Summary
EXPEDITION clinical program seems to satisfy U.S. requirements for firm’s COPD bronchodilators; now all Novartis needs is approval, some clinical differentiation – and perhaps a marketing partner.